We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

164 hedge funds and large institutions have $1.52B invested in Rocket Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

341% more call options, than puts

Call options by funds: $4.54M | Put options by funds: $1.03M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

13% more capital invested

Capital invested by funds: $1.34B → $1.52B (+$177M)

13% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 54

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

1% more funds holding

Funds holding: 163 → 164 (+1)

3.73% less ownership

Funds ownership: 98.63% → 94.9% (-3.7%)

Holders
164
Holders Change
+1
Holders Change %
+0.61%
% of All Funds
2.57%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
18
Increased
61
Reduced
54
Closed
17
Calls
$4.54M
Puts
$1.03M
Net Calls
+$3.51M
Net Calls Change
+$371K

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$20.9M
2
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$8.48M
3
PA
Perceptive Advisors
New York
+$6.07M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.09M
5
PHS
PFM Health Sciences
California
+$4.82M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$19.4M
2
State Street
State Street
Massachusetts
-$17M
3
LGM
Logos Global Management
California
-$13.1M
4
BlackRock
BlackRock
New York
-$6.69M
5
WP
Woodline Partners
California
-$5.59M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
51
Barclays
United Kingdom
$2.85M -$362K -17,925 -11%
EAM
52
EFG Asset Management
Oregon
$2.78M +$39.8K +1,968 +1%
Jane Street
53
Jane Street
New York
$2.72M +$2.27M +112,289 +457%
HWAM
54
Hennion & Walsh Asset Management
New Jersey
$2.49M +$436K +21,597 +21%
AllianceBernstein
55
AllianceBernstein
Tennessee
$2.46M -$1.03M -51,111 -29%
Swiss National Bank
56
Swiss National Bank
Switzerland
$2.4M -$131K -6,500 -5%
NLVP
57
New Leaf Venture Partners
New York
$2.35M – – –
DekaBank Deutsche Girozentrale
58
DekaBank Deutsche Girozentrale
Germany
$1.8M – – –
CS
59
Credit Suisse
Switzerland
$1.74M +$341K +16,865 +24%
Citigroup
60
Citigroup
New York
$1.71M -$3.31M -163,726 -66%
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
$1.66M -$175K -8,661 -9%
Rockefeller Capital Management
62
Rockefeller Capital Management
New York
$1.63M +$283K +14,000 +21%
SF
63
Synovus Financial
Georgia
$1.61M -$109K -5,412 -6%
RHJA
64
Rice Hall James & Associates
California
$1.57M +$66.9K +3,311 +4%
GTC
65
Ghost Tree Capital
New York
$1.49M +$1.52M +75,000 New
Manulife (Manufacturers Life Insurance)
66
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.44M +$215K +10,637 +17%
Wells Fargo
67
Wells Fargo
California
$1.35M +$69.8K +3,453 +5%
California State Teachers Retirement System (CalSTRS)
68
California State Teachers Retirement System (CalSTRS)
California
$1.34M -$103K -5,092 -7%
PFM
69
Privium Fund Management
Netherlands
$1.19M – – –
Macquarie Group
70
Macquarie Group
Australia
$1.15M – – –
BMSSC
71
B. Metzler seel. Sohn & Co
Germany
$1.13M +$609K +30,132 +112%
State of Wisconsin Investment Board
72
State of Wisconsin Investment Board
Wisconsin
$1.12M -$102K -5,054 -8%
TD Asset Management
73
TD Asset Management
Ontario, Canada
$1.11M +$325K +16,100 +40%
BG
74
Bellevue Group
Switzerland
$1.1M +$384K +19,000 +52%
HCA
75
Harbor Capital Advisors
Illinois
$1.1M +$40.6K +2,009 +4%
1 2
3
4 5

RCKT Hedge Fund Activity: Q2 2023 in Review

164 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2023, worth a combined $1.52B — up 13% from $1.34B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new RCKT positions and 17 closed out — a net gain of 1 holder — while 61 added to existing stakes and 54 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $20.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.4M sold.

  • 164 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2023, up from 163 in Q1 2023.
  • Funds reported $1.52B of Rocket Pharmaceuticals stock for Q2 2023, up 13% quarter-over-quarter.
  • 18 funds opened new Rocket Pharmaceuticals positions in Q2 2023 and 17 closed out, a net change of +1 holder.
  • The largest Rocket Pharmaceuticals buyer in Q2 2023 was Wellington Management Group, an estimated $20.9M added.
  • The largest Rocket Pharmaceuticals seller in Q2 2023 was RA Capital Management, an estimated $19.4M sold.

Based on aggregated 13F filings for Q2 2023.